Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A

This article discusses a groundbreaking clinical trial investigating the use of OC-1, a new type of CAR T-cell therapy, for patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoma (T-LL). The therapy involves modifying a patient’s own T-cells to target CD1a, a protein found on certain cancer cells. This innovative approach aims to provide a potential treatment option for patients who have not responded to standard therapies.

Related diseases and areas:

• T-cell type acute leukaemia

AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING AN ANTI-SLAMF7 CD28/CD3-ZETA CHIMERIC ANTIGEN RECEPTOR

Clinical trials are studying AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR ENCODING AN ANTI-SLAMF7 CD28/CD3-ZETA CHIMERIC ANTIGEN RECEPTOR in people with multiple myeloma. These studies are looking at feasibility, safety, and antitumor activity, as well as how many patients have a response to treatment. The main target population is patients with multiple myeloma.

Related diseases and areas:

• Plasma cell myeloma

Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19

This article explores the use of autologous T-cells transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) directed against CD19 in clinical trials. This innovative therapy, known as CAR T-cell therapy, is being investigated for various conditions, including relapsed or refractory B-cell malignancies and certain autoimmune diseases. The trials aim to assess the safety, efficacy, and feasibility of this personalized treatment approach in patients who have not responded well to conventional therapies.

Related diseases and areas:

• Autoimmune disorder
• Marginal zone lymphoma
• B-cell lymphoma recurrent
• Follicular lymphoma
• Diffuse large B-cell lymphoma
• Acute lymphocytic leukaemia…

AUTOLOGOUS T-CELLS TRANSDUCED WITH THE LENTIVIRAL LV-R11KEA ENCODING T-CELL RECEPTOR TARGETING PATIENT-SPECIFIC TUMOR-ASSOCIATED ANTIGENS

Clinical trials are investigating AUTOLOGOUS T-CELLS TRANSDUCED WITH THE LENTIVIRAL LV-R11KEA ENCODING T-CELL RECEPTOR TARGETING PATIENT-SPECIFIC TUMOR-ASSOCIATED ANTIGENS in people with solid tumors and cutaneous melanoma. These studies are looking at safety, tolerability, and how well the treatment works, including tumor response and progression-free survival.

AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS

Clinical trials of AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS are studying this treatment in people with multiple sclerosis, especially relapsing-remitting multiple sclerosis (RRMS). The main goals are to check whether it helps control disease activity and whether it is safe when used with first-line immunotherapy.

Related diseases and areas:

• Nervous system disorder
• Multiple sclerosis

Autologous Tumor Lysate-Loaded Dendritic Cells

This article examines ongoing clinical trials investigating the use of autologous tumor lysate-loaded dendritic cell vaccines for treating different types of cancer. These innovative immunotherapy treatments aim to harness the power of a patient’s own immune system to fight cancer cells. The trials focus on various cancer types, including neuroendocrine tumors, soft tissue sarcomas, glioblastoma, and colorectal cancer, exploring the safety, efficacy, and potential benefits of this personalized approach to cancer treatment.

Related diseases and areas:

• Neuroendocrine tumour
• Soft tissue sarcoma
• Colorectal cancer metastatic
• Glioblastoma

Autumn Crocus Fresh Flower Fluid Extract (1:15-25), Extraction Solvent Ethanol 96% (V/V)

This article examines the use of Autumn Crocus Fresh Flower Fluid Extract (1:15-25), Extraction Solvent Ethanol 96% (V/V) in clinical trials. This extract, also known as colchicine, is being studied for its potential benefits in treating atrial fibrillation and gout. We’ll explore two ongoing trials that aim to assess the efficacy and safety of this compound in different medical conditions.

Related diseases and areas:

• Atrial fibrillation
• Gout

Avacincaptad Pegol

Clinical trials are studying Avacincaptad Pegol in people with geographic atrophy. These studies mainly look at long-term safety and other research outcomes in patients who completed earlier trial treatment. The data here come from a Phase 3 extension study.

Related diseases and areas:

• Dry age-related macular deg…

Avacopan

Clinical trials are investigating Avacopan in people with ANCA-associated vasculitis, including adults with severe kidney disease and children with active disease. These studies look at how well Avacopan works, how safe it is, and how the body handles it when used with standard treatment.

Avalglucosidase Alfa

Clinical trials of Avalglucosidase Alfa are studying how well it works and how safe it is in people with Pompe disease, including babies, children, and adults. These studies look at outcomes such as survival, muscle strength, walking ability, lung function, and side effects. Some trials also focus on long-term access or on people whose condition is stable or getting worse on current treatment.

Related diseases and areas:

• Glycogen storage disease ty…

Avalotcagene Ontaparvovec

Avalotcagene Ontaparvovec is an innovative gene therapy being studied in clinical trials for the treatment of late-onset Ornithine Transcarbamylase (OTC) deficiency. This rare genetic disorder affects the body’s ability to process nitrogen, leading to potentially dangerous ammonia buildup in the blood. The clinical trials aim to evaluate the safety and effectiveness of this therapy in improving OTC function and maintaining safe ammonia levels in patients aged 12 and older.

Related diseases and areas:

• Ornithine transcarbamoylase…

Avapritinib

Clinical trials are investigating Avapritinib in different patient groups, including children with certain solid tumors and adults with mastocytosis. These studies look at safety, dose finding, and how well the treatment works. The trials include early-phase and later-phase research.

Related diseases and areas:

• Neoplasm malignant
• Indolent systemic mastocytosis

Avatrombopag

Avatrombopag is an oral thrombopoietin receptor agonist that has shown promise in treating various conditions associated with low platelet counts. This article explores the use of avatrombopag in clinical trials for conditions such as severe aplastic anemia, immune thrombocytopenia, and chemotherapy-induced thrombocytopenia. We’ll examine its efficacy, safety, and potential benefits for patients with these challenging blood disorders.

Related diseases and areas:

• Immune thrombocytopenia

Avb-101

A groundbreaking clinical trial is underway to evaluate AVB-101, a novel gene therapy for patients with Frontotemporal Dementia caused by Progranulin Mutations (FTD-GRN). This Phase 1/2 study aims to assess the safety and potential effectiveness of AVB-101 when administered directly into the brain. The trial offers hope for individuals affected by this rare form of dementia and their families.

Related diseases and areas:

• Frontotemporal dementia

Avelumab

Clinical trials with Avelumab are studying how well it works in different cancers and how safe it is in specific patient groups. These studies include maintenance treatment, first-line treatment, and combination therapy in adults and children with advanced, metastatic, or recurrent tumors. The trials measure outcomes such as survival, tumor response, disease control, and quality of life.

Related diseases and areas:

• Penile cancer
• Central nervous system neop…
• Bladder cancer
• Renal cell carcinoma
• Cervix carcinoma
• Squamous cell carcinoma of …

Avibactam Sodium

Clinical trials of Avibactam Sodium are studying aztreonam-avibactam in young patients with serious gram-negative bacterial infections. These studies look at pharmacokinetics, safety, and tolerability in neonates, infants, and children with infections such as sepsis, urinary tract infection, pneumonia, and bloodstream infection.

Related diseases and areas:

• Sepsis
• Pneumonia
• Abdominal infection
• Infection
• Haematological infection
• Bacterial infection

AVTX-009

Researchers are currently investigating AVTX-009, a promising new medication for people suffering from moderate to severe Hidradenitis Suppurativa (HS). The LOTUS study is a Phase 2 clinical trial designed to evaluate how effectively and safely AVTX-009 works compared to a placebo. This randomized trial involves different dosing schedules of AVTX-009 administered as subcutaneous injections. Participants will receive treatment for up to 16 weeks, with researchers monitoring improvements in HS symptoms such as reduction in abscesses, inflammatory nodules, and draining fistulas. This trial represents an important step in developing new treatment options for this challenging skin condition.

Related diseases and areas:

• Hidradenitis

Avutometinib

Clinical trials of Avutometinib are studying how well it works and how safe it is in specific cancers. The main trials here include people with recurrent low-grade serous ovarian cancer and patients with non-small cell lung cancer. These studies look at response to treatment, disease control, and other outcomes.

Related diseases and areas:

• Ovarian cancer recurrent
• Non-small cell lung cancer

Axitinib

Clinical trials are studying Axitinib in several cancers, mainly kidney cancer and some other solid tumors. These studies look at how well it works, how safe it is in different combinations, and which patients may benefit most. Many trials focus on metastatic or advanced disease, while others test earlier treatment or special groups such as children.

Related diseases and areas:

• Neoplasm malignant
• Metastatic renal cell carci…
• Non-Hodgkin’s lymphoma
• Renal cell carcinoma
• Ependymoma malignant
• Plasma cell myeloma

AZD0022

AZD0022 is an innovative oral drug being studied in a first-in-human clinical trial for patients with advanced cancers that have a specific genetic mutation called KRAS G12D. This Phase I/IIa study, known as ALAFOSS-01, is investigating how safe and effective AZD0022 is when used alone or in combination with other cancer treatments, particularly in non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. The trial follows a modular design to systematically evaluate different dosing strategies and potential combinations, with a focus on understanding how the drug works in the body and whether it can effectively shrink tumors in patients with this specific mutation.

Related diseases and areas:

• Colorectal cancer
• Small cell lung cancer
• Adenocarcinoma pancreas

AZD0120

Clinical trials are investigating AZD0120 in people with relapsed or refractory multiple myeloma, a cancer that has returned or no longer responds to treatment. These studies aim to compare AZD0120 with standard therapy and measure how well it works and how safe it is. The main focus is on adults with this blood cancer in a Phase 3 trial.

AZD0292

Clinical trials are investigating AZD0292 in people with bronchiectasis and chronic pseudomonas aeruginosa colonization. These studies aim to assess how well AZD0292 works, how safe it is, and how it moves through the body over time. The main focus is on adults with non-cystic fibrosis bronchiectasis and long-term PsA colonization.

Azd0305

Clinical trials are studying Azd0305 in adults with multiple myeloma. These studies aim to check safety, tolerability, and early signs of benefit, both when Azd0305 is used alone and with other cancer treatments.

Related diseases and areas:

• Plasma cell myeloma

AZD0516

Clinical trials are investigating AZD0516 in adults with metastatic prostate cancer. These studies aim to learn how safe AZD0516 is, how well it works, and which dose may be best, both alone and with other cancer treatments. The main trial is in a phase 1/2 setting.

Related diseases and areas:

• Prostate cancer metastatic

Azd0901

Azd0901 is being studied in several clinical trials for people with advanced cancers, especially gastric and gastroesophageal junction cancer. These trials look at safety, tolerability, and how well Azd0901 works alone or with other cancer drugs in different patient groups.

Related diseases and areas:

• Gastrooesophageal cancer
• Biliary cancer metastatic
• Adenocarcinoma gastric
• Gastric cancer
• Oesophageal adenocarcinoma
• Adenocarcinoma pancreas

AZD1163

Clinical trials are investigating AZD1163 in adults with moderately to severely active rheumatoid arthritis. The main goal is to check whether it can improve symptoms and inflammation, and to assess safety and clinical efficacy compared with placebo.

Azd2693 Sodium

A groundbreaking clinical trial is underway to assess the effectiveness, safety, and tolerability of AZD2693 Sodium, a promising new drug for treating non-cirrhotic non-alcoholic steatohepatitis (NASH) with fibrosis. This study focuses on adult participants who carry a specific genetic marker, offering hope for a targeted treatment approach in NASH management.

Azd3427

Clinical trials are investigating Azd3427 in people with heart failure and related circulation problems. These studies look at whether it can improve blood flow in the lungs and kidneys, and they measure safety and treatment effect in specific patient groups.

Related diseases and areas:

• Renal impairment
• Pulmonary arterial hyperten…
• Cardiac failure

Azd3470

Clinical trials are investigating Azd3470 in people with advanced solid tumours that are MTAP deficient. The studies are looking at safety, tolerability, and the recommended dose for later testing, both as a single treatment and with anti-cancer medicines.

Related diseases and areas:

• Neoplasm malignant

AZD3632

Clinical trials are investigating AZD3632 in adults with relapsed or refractory acute leukemia and myelodysplastic syndromes with HOX gene overexpression. These studies aim to assess safety, tolerability, how the treatment works, and how it moves through the body over time. The trial is in Phase 1/2 and includes people with advanced blood cancers.

Related diseases and areas:

• Myelodysplastic syndrome
• Acute lymphocytic leukaemia…
• Acute myeloid leukaemia ref…
• Acute myeloid leukaemia rec…

AZD4360

Clinical trials are investigating AZD4360 in adults with advanced solid tumors, including certain stomach, bile duct, and pancreatic cancers. The studies aim to learn about safety, how well AZD4360 works, and how it moves through the body. They also look for a dose that can be used in later studies.

Related diseases and areas:

• Oesophageal carcinoma
• Pancreatic carcinoma
• Gastric cancer
• Biliary neoplasm

AZD4512

Clinical trials are studying AZD4512 in people with B-cell blood cancers. These studies aim to learn about safety, tolerability, and how well AZD4512 may work in non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The trials include adults with relapsed or refractory disease, meaning the cancer came back or did not respond well to past treatment.

Azd5004

AZD5004 is a novel drug currently undergoing clinical trials for the treatment of obesity and type 2 diabetes. This article explores the ongoing research into AZD5004’s safety, efficacy, and potential benefits for patients struggling with weight management and blood sugar control. We’ll examine the various phases of clinical trials and what they aim to discover about this promising new medication.

Related diseases and areas:

• Obesity
• Overweight

AZD5148

Clinical trials are investigating HUMANISED IGG1 KAPPA (YTE) MONOCLONAL ANTIBODY AGAINST CLOSTRIDIOIDES DIFFICILE, TOXIN B in people with recurrence of Clostridioides difficile infection. The study aims to evaluate efficacy against recurrence, with a focus on patients receiving standard antibacterial treatment. This article summarizes the trial design, phase, target population, and main outcome being measured.

AZD5335

Clinical trials are investigating AZD5335 in women with advanced platinum-resistant epithelial ovarian cancer. The studies are looking at how well AZD5335 works compared with other treatments, and they also measure safety and disease control. One large phase 3 trial is separating patients by FRα tumor level.

Related diseases and areas:

• Ovarian epithelial cancer

Azd5462

Clinical trials are investigating Azd5462 in people with chronic heart failure. These studies are looking at whether different doses are safe and effective, especially in stable patients. The main goal is to see how heart structure and function change during treatment.

Related diseases and areas:

• Cardiac failure chronic

Azd5492

Clinical trials are investigating Azd5492 in adults with B-cell blood cancers. These studies aim to learn whether Azd5492 is safe and whether it may work alone or with other cancer treatments. The trial data shown here focuses on people with relapsed or refractory B-cell malignancies.

Related diseases and areas:

• Neoplasm malignant

AZD6234

Clinical trials are investigating AZD6234 as part of studies for weight loss in people with obesity or overweight. These trials look at safety, tolerability, and how well AZD6234 works alone or with AZD9550. The studies include adults with obesity or overweight, with or without type 2 diabetes.

Related diseases and areas:

• Overweight
• Obesity

Azd7798

Azd7798 is being studied in clinical trials for Crohn’s disease, including adults with ileal Crohn’s disease who have an ileostomy. These trials are checking safety, tolerability, and how well Azd7798 may help people reach remission.

Related diseases and areas:

• Crohn’s disease

Azd8205

Clinical trials are investigating Azd8205 in people with advanced or metastatic solid cancers, including B7-H4-selected endometrial cancer. These studies aim to assess safety, tolerability, and how well Azd8205 works, including the best dose and survival outcomes.

Related diseases and areas:

• Endometrial cancer metastatic
• Endometrial cancer
• Breast cancer
• Non-small cell lung cancer
• Ovarian cancer
• Biliary neoplasm

Azd8421

This article discusses a groundbreaking clinical trial investigating the use of AZD8421, a new drug being tested for treating advanced or metastatic solid tumors. The study focuses on patients with ER+HER2- advanced breast cancer and high-grade serous ovarian cancer. The trial aims to assess the safety, effectiveness, and how the body processes AZD8421 when used alone or in combination with other cancer drugs.

Related diseases and areas:

• Ovarian cancer

Azd8630

AZD8630 is an experimental drug being studied for the treatment of asthma. This article summarizes the ongoing clinical trials evaluating the safety, effectiveness, and proper dosing of AZD8630 in healthy volunteers and patients with asthma. The trials aim to determine if AZD8630 can improve asthma control and reduce exacerbations when added to standard asthma medications.

Related diseases and areas:

• Asthma

Azd9550

AZD9550 is an investigational drug currently undergoing clinical trials for the treatment of Non-alcoholic Steatohepatitis (NASH), a severe form of liver disease often associated with obesity and type 2 diabetes. These trials aim to assess the safety, tolerability, and effectiveness of AZD9550 in various patient populations, including healthy individuals and those with obesity or diabetes. The studies are designed to evaluate different dosing regimens and administration methods, providing valuable insights into the drug’s potential as a new therapeutic option for NASH.

Related diseases and areas:

• Overweight
• Obesity

Azenosertib

Azenosertib, also known as ZN-c3, is an innovative drug currently being studied in clinical trials for various types of cancer. This article explores the ongoing research into Azenosertib’s potential as a treatment for uterine serous carcinoma, triple-negative breast cancer, pancreatic cancer, and other solid tumors. We’ll look at how it works, its combination with other drugs, and what these trials mean for cancer patients.

Related diseases and areas:

• Ovarian cancer recurrent
• Colorectal cancer metastatic
• Fallopian tube cancer
• Papillary serous endometria…
• Ovarian cancer
• Malignant peritoneal neoplasm

Azithromycin Dihydrate

This article explores the use of Azithromycin Dihydrate in clinical trials for various medical conditions. Azithromycin is an antibiotic medication that has been studied for its potential benefits in treating lung transplant complications, eye infections, and inflammatory bowel diseases. We’ll examine the key findings from these trials and discuss how this drug may impact patient care in different medical fields.

Related diseases and areas:

• Chronic obstructive pulmona…
• Breast cancer
• Breast cancer female